About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Artiva Biotherapeutics, Inc. (ARTV) Insider Trading
28 open-market trades reported since Jun 16, 2026: 16 purchases worth $10.0M and 12 sales worth $2.00M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Fred Aslan | CEO | 0 | $0 | 4 | $1.54M |
| Christopher Horan | Chief Tech Operations Officer | 0 | $0 | 2 | $186K |
| Jennifer Bush | COO | 0 | $0 | 2 | $151K |
| Subhashis Banerjee | Chief Medical Officer | 0 | $0 | 4 | $124K |
| Ra Capital Management, L.P. | Director | 16 | $10.0M | 0 | $0 |
All trades
| Filed | Insider | Type | Value | Score | 3 mo. after |
|---|---|---|---|---|---|
| Oct 7 | Fred AslanCEO | ▼ SELL10b5-1 | $169K | ||
| Oct 6 | Fred AslanCEO | ▼ SELL | $422K | ||
| Oct 6 | Christopher HoranChief Tech Operations Officer | ▼ SELL | $71K | ||
| Oct 6 | Jennifer BushCOO | ▼ SELL | $57K | ||
| Oct 6 | Subhashis BanerjeeChief Medical Officer | ▼ SELL | $8K | ||
| Sep 9 | Fred AslanCEO | ▼ SELL10b5-1 | $256K | ||
| Sep 4 | Fred AslanCEO | ▼ SELL | $690K | ||
| Sep 4 | Christopher HoranChief Tech Operations Officer | ▼ SELL | $116K | ||
| Sep 4 | Jennifer BushCOO | ▼ SELL | $94K | ||
| Sep 4 | Subhashis BanerjeeChief Medical Officer | ▼ SELL | $12K | ||
| Aug 31 | Subhashis BanerjeeChief Medical Officer | ▼ SELL10b5-1 | $99K | ||
| Aug 19 | Subhashis BanerjeeChief Medical Officer | ▼ SELL10b5-1 | $5K | ||
| Jul 31 | Ra Capital Management, L.P.Director | ▲ BUY | $248K | 26 | |
| Jul 31 | Ra Capital Management, L.P.Director | ▲ BUY | $208K | 26 | |
| Jul 28 | Ra Capital Management, L.P.Director | ▲ BUY | $413K | 30 | |
| Jul 23 | Ra Capital Management, L.P.Director | ▲ BUY | $1.15M | 37 | |
| Jul 23 | Ra Capital Management, L.P.Director | ▲ BUY | $835K | 34 | |
| Jul 23 | Ra Capital Management, L.P.Director | ▲ BUY | $596K | 34 | |
| Jul 23 | Ra Capital Management, L.P.Director | ▲ BUY | $58K | 12 | |
| Jul 20 | Ra Capital Management, L.P.Director | ▲ BUY | $1.36M | 26 | |
| Jul 20 | Ra Capital Management, L.P.Director | ▲ BUY | $71K | 12 | |
| Jul 14 | Ra Capital Management, L.P.Director | ▲ BUY | $135K | 19 | |
| Jul 14 | Ra Capital Management, L.P.Director | ▲ BUY | $59K | 12 | |
| Jun 29 | Ra Capital Management, L.P.Director | ▲ BUY | $275K | 19 | −3.0% |
| Jun 29 | Ra Capital Management, L.P.Director | ▲ BUY | $17K | 9 | −4.1% |
| Jun 16 | Ra Capital Management, L.P.Director | ▲ BUY | $3.35M | 26 | +21.6% |
| Jun 16 | Ra Capital Management, L.P.Director | ▲ BUY | $1.11M | 26 | −3.1% |
| Jun 16 | Ra Capital Management, L.P.Director | ▲ BUY | $139K | 19 | −4.2% |